Such as IL‐33 can be used as an early predictor of the efficacy of cetuximab in the treatment of colorectal cancer and the reduction of the toxicity of platinum‐based chemotherapy drugs to gastric cancer cells [91, 92, 93]. This evidence concerns the gene IL33 and colorectal cancer.